Data completeness
0/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Diasone Sodium (sulfoxone sodium) is an oral delayed-release tablet indicated for treating leprosy and dermatitis herpetiformis. The drug is a sulfone derivative that works by suppressing inflammatory and immune responses in these chronic skin conditions. It represents a niche therapeutic agent with a long clinical history in dermatology.
Pre-Launch
Pre-launch stage suggests early-stage commercial team building focused on regulatory clearance, market access, and launch readiness rather than peak-cycle optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Diasone Sodium in pre-launch phase offers career development in regulatory navigation, niche-market commercialization, and specialty dermatology positioning. This product suits professionals interested in rare disease or specialty pharma careers where deep stakeholder relationships and regulatory expertise drive success.
Brand ManagerProduct Manager
Worked on DIASONE SODIUM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.